Skip to main content

Alcohol Abuse

3
Pipeline Programs
6
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

AfaSci
AfaSciCA - Redwood City
1 program
1
AFA-281Phase 21 trial
Active Trials
NCT06710431Not Yet Recruiting36Est. Dec 2027
Sound Pharmaceuticals
1 program
1
PrazosinPhase 21 trial
Active Trials
NCT01518972Completed30Est. Jun 2012
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
1
ProtandimPhase 21 trial
Active Trials
NCT00936000Completed38Est. Sep 2010
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
2 programs
Youth AccessN/A1 trial
eHealth Coping Skills TrainingN/A1 trial
Active Trials
NCT02448134Completed7,379Est. Jun 2020
NCT02984241Completed456Est. Nov 2022
Purdue Pharma
Purdue PharmaCT - Stamford
1 program
Aversive CueN/A1 trial
Active Trials
NCT03648840Terminated84Est. May 2022
Alliance Pharmaceuticals
1 program
Computerized screening and brief physician adviceN/A1 trial
Active Trials
NCT00849589Withdrawn0Est. Dec 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AfaSciAFA-281
Sound PharmaceuticalsPrazosin
Colorado TherapeuticsProtandim
Oregon TherapeuticseHealth Coping Skills Training
Purdue PharmaAversive Cue
Oregon TherapeuticsYouth Access
Alliance PharmaceuticalsComputerized screening and brief physician advice

Clinical Trials (7)

Total enrollment: 8,023 patients across 7 trials

NCT06710431AfaSciAFA-281

A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder

Start: Oct 2025Est. completion: Dec 202736 patients
Phase 2Not Yet Recruiting
NCT01518972Sound PharmaceuticalsPrazosin

Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder

Start: Sep 2009Est. completion: Jun 201230 patients
Phase 2Completed
NCT00936000Colorado TherapeuticsProtandim

Antioxidant Replacement Therapy in Patients With Alcohol Abuse

Start: Jun 2009Est. completion: Sep 201038 patients
Phase 2Completed
NCT02984241Oregon TherapeuticseHealth Coping Skills Training

E-Health Coping Skills Training for Women Whose Partner Has a Drinking Problem

Start: Oct 2019Est. completion: Nov 2022456 patients
N/ACompleted
NCT03648840Purdue PharmaAversive Cue

Human Alcohol Seeking Despite Aversion

Start: Apr 2018Est. completion: May 202284 patients
N/ATerminated
NCT02448134Oregon TherapeuticsYouth Access

A Community-Based Strategy for Preventing Underage Drinking

Start: Sep 2014Est. completion: Jun 20207,379 patients
N/ACompleted
NCT00849589Alliance PharmaceuticalsComputerized screening and brief physician advice

Computerized Screening and Brief Physician Advice to Reduce Teen Drinking

Start: Jan 2010Est. completion: Dec 20140
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.